CAI Share Price Performance
US$16.95
-11.05 (-39.46%)
55.5% undervalued intrinsic discount
US$38.11
Fair Value
Price US$16.95
AnalystConsensusTarget US$38.11
AnalystLowTarget US$26.23
Talos US$74.17
Fair ValueUS$38.11
Share Pricen/a
Caris Life Sciences, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 23 Fair Values set on narratives written by author
CAI Community Narratives
AN
Fair Value US$38.11 55.5% undervalued intrinsic discount
Whole Genome And MRD Adoption Will Support A Stronger Long Term Thesis
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$26.23 35.4% undervalued intrinsic discount
Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
TA
Fair Value US$74.17 77.1% undervalued intrinsic discount
The "Google Maps" of Cancer Biology – Data is the Moat
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
The "Google Maps" of Cancer Biology – Data is the Moat
Caris Life Sciences ($CAI) is the "Big Data" play of the biotech world. While companies like Recursion ($RXRX) use AI to find drugs, Caris uses AI to tell doctors which drug to use for a specific patient.Read more
78
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future
Catalysts About Caris Life Sciences Caris Life Sciences provides comprehensive molecular profiling and data-driven precision medicine solutions across tissue and blood for oncology and related applications. What are the underlying business or industry changes driving this perspective?Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$26.23
35.4% undervalued intrinsic discount
Fair Value
Profit Margin
10.71%
Future PE
77.43x
Price in 2029
US$32.26
Whole Genome And MRD Adoption Will Support A Stronger Long Term Thesis
Catalysts About Caris Life Sciences Caris Life Sciences is a precision medicine company focused on whole exome, whole transcriptome and whole genome sequencing across tissue and blood to inform cancer therapy selection, monitoring and early detection. What are the underlying business or industry changes driving this perspective?Read more
35
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$38.11
55.5% undervalued intrinsic discount
Fair Value
Profit Margin
15.32%
Future PE
66.96x
Price in 2029
US$46.82
Early Cancer Detection And MRD Leadership Will Deliver Outsized Long-Term Oncology Testing Upside
Catalysts About Caris Life Sciences Caris Life Sciences is a precision medicine company that leverages Whole Exome, Whole Transcriptome and whole genome sequencing, cloud computing and AI to transform cancer diagnostics, treatment selection and prevention. What are the underlying business or industry changes driving this perspective?Read more
36
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$45
62.3% undervalued intrinsic discount
Fair Value
Profit Margin
26.33%
Future PE
42.08x
Price in 2028
US$55.34
Trending Discussion
Recently Updated Narratives
TA
Caris Life Sciences ($CAI): The "Big Data" Juggernaut Just Delivered a 94% Growth Surprise
Fair Value: US$74.17 77.1% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future
Fair Value: US$26.23 35.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Whole Genome And MRD Adoption Will Support A Stronger Long Term Thesis
Fair Value: US$38.11 55.5% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Caris Life Sciences, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.90
- 66.63%
- -66.25%
- 65.6%
About CAI
- Founded
- 2008
- Employees
- 1846
- CEO
- WebsiteView website
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
